Presentation is loading. Please wait.

Presentation is loading. Please wait.

A new era in home-based Screening and Monitoring

Similar presentations


Presentation on theme: "A new era in home-based Screening and Monitoring"— Presentation transcript:

1 A new era in home-based Screening and Monitoring
Confidential

2 Overview Advanced Biomarker Ltd. is a technology of the Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute (LTRI) The scope: Development and commercialization of the first certified home-based clinical diagnostic platform The niche: Advanced Biomarkers LLC capitalizes on our: unique, ultra-sensitive diagnostic technologies global brand powerful marketing capacities great business-building expertise Confidential

3 Assay #1 : PSA

4 POC Test-1: PSA PSA is one of the most widely used stand-alone biomarkers in the clinic for the screening and monitoring of prostate cancer. All men over the age of 40 should monitor their PSA levels regularly (1-2 per year) while men with prostate cancer should monitor more regularly (2-4 times per year) PSA is the most informative blood prostate cancer biomarker. Critical clinical PSA cut-offs: pg/ml (for screening purposes) 20-50 pg/ml (for monitoring post prostatectomy patients)

5 The problem Currently in China there is a drastic under-screening and monitoring of PSA levels in men according to the Chinese Urology Association. Early detection of prostate cancer considerably raises the chances of survival. PSA tests are solely performed in central clinical labs (hospitals, private diagnostic centers etc). Prostate cancer patients are required to re-currently visit their doctors and get subjected to traditional venous phlebotomy. From a patient’s perspective, frequent hospital visits are associated with: Increased stress Increased time consumption Schedule conflicts

6 Our solution For the first time, Advanced Biomarker Ltd has delivered an ultra-sensitive home-based kit (1pg/ml) that enables a simple, safe, and accurate PSA testing for both screening and monitoring purposes Our in-house developed ELISA-based technology is able to detect PSA level increases at very low concentrations (well-below the critical clinical cut-offs) Our mail-based technology requires miniscule amounts of capillary blood -50ul (0.05ml) taken from the finger tip of patients and provides reliable results. A built-in cell phone app allows patients and physicians to trend their PSA levels over time.

7 How it works 2. Through our automated mailing system blood is delivered to our central facility 1. Upon request patient receives our finger-prick kit at doctors office or through the mail Central Certified PSA Examination Center 3. Using our cloud database patient can securely track his PSA history

8 Superior to all competitors

9 The PSA market in China There are an estimated 10 million men currently living with prostate cancer in China, many cases of which are undetected due to insufficient screening. These men should monitor their PSA levels frequently (2-4 times per year) There are approximately 300 million men in China who require regular PSA screening (1-2 times per year) In 2015 there were approximately new prostate cancer cases reported. The rate of prostate cancer is growing by 12.1% annually in China as China has one of the fastest aging populations in the world. The team at Advanced Biomarker and Mt. Sinai have developed the only home-based, easy to use, ultra-sensitive, accurate and reliable PSA test available for both screening AND monitoring PSA levels in men.

10 CA-125 Home Based Ovarian Cancer Screen
What is next for CA-125 Home Based Ovarian Cancer Screen Confidential

11 Mount Sinai Hospital - ACDC Laboratory
Mount Sinai Hospital - ACDC Laboratory 60 Murray Street, 6th Floor, Room L6-201 (Box 32) Toronto, ON, M5T 3L9 advancedbiomarker.ca


Download ppt "A new era in home-based Screening and Monitoring"

Similar presentations


Ads by Google